HUV drugs: Key market research findings
- Increased funding for upscaling the HIV drugs consumption
- Nucleoside reverse transcriptase inhibitors segment to exceed US $5,500 million by 2019
Technavio has added a new market research report on the global HIV drugs market, which is expected to grow at a CAGR of more than 4% between 2015 and 2019. Rise in HIV patient population, and the development of HIV drugs as one of the most promising therapeutic areas, is encouraging this market’s growth. Currently, the Americas dominate the global market for HIV drugs, however, the EMEA is expected to be the highest revenue-generating segment in this market during the forecast period. Factors like the growing patient population and various initiatives taken by the government in this region are responsible for its high revenue generation capacity of more than US $7,500 million in the next four years.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
Various governments and NGOs are aiding hospitals and clinical laboratories for effective HIV treatment. Several market vendors like Gilead Sciences, GlaxoSmithKline, Pfizer, Johnson & Johnson, and Merck are offering financial assistance to patients to opt for antiretroviral therapy at reasonable costs. Donor governments are providing resources to the middle- and low-income countries. For instance, the US has emerged as the single largest donor worldwide. Brazil, Botswana, Senegal, Ethiopia, Zambia, Thailand, and the United Republic of Tanzania are some of the countries that offer free treatment to individuals with AIDS.
“Nucleoside reverse transcriptase inhibitors are the most widely used drug classes for treating HIV infection. These inhibitors act as chain terminators as they do not have the 3′-hydroxyl group, preventing the addition of natural nucleosides into the DNA strand and terminating the production of new virions,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research
The leading vendors in the global HIV drugs market are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck. This market is highly competitive and contains numerous local and international vendors who increasingly compete with each other to gain prominence in this market. Local vendors in this market are also gaining traction as they have the ability to supply generic versions of the branded drugs to treat HIV-related conditions.
A more detailed analysis is available in the Technavio report, Global HIV Drugs Market 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
Further Reading:
